BerGenBio ASA: Results for the third quarter 2019
· FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML) · High Impact oral presentation of 2L NSCLC clinical data at SITC · Met primary and secondary endpoints in non-small cell lung cancer (NSCLC) Phase II clinical trial in patients previously treated with chemotherapy (cohort A) · Proprietary composite AXL tumor immune score (cAXL) identified patients that have shown very durable response and significantly prolonged median Progression Free Survival (mPFS) · Proprietary gene signature identified 2L NSCLC patients that had durable benefit and was independent of